Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization

• Main Authors: Jaime Piquero-Casals (Author), Daniel Morgado-Carrasco (Author), Yolanda Gilaberte (Author), Rubén Del Rio (Author), Antonio Macaya-Pascual (Author), Corinne Granger (Author), José Luis López-Estebaranz (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1007/s13555-020-00425-4; 2193-8210; 2190-9172
• Keywords: Actinic keratosis; Chemical peels; Cutaneous field cancerization; Photoaging; Photo-carcinogenesis; Photodynamic therapy; Dermatology; RL1-803
• Source: Dermatology and Therapy, Vol 10, Iss 5, Pp 903-915 (2020)

Abstract Field cancerization (FC) is a chronic disease involving multiple clinical and subclinical actinic keratoses (AK) on large photo-exposed surfaces with multifocal areas of dysplasia and precancerous changes. Patients and treatment must be properly monitored and managed to avoid aggravation and progression of the disease. Management of actinic keratoses includes lesion-directed treatments, such as cryotherapy and field-directed therapies. Field-directed therapies may have the potential to address subclinical damage, reduce AK recurrence rates and potentially reduce the risk of squamous cell carcinoma development. Multiple studies have demonstrated the efficacy of field-directed treatments, including 5-fluorouracil, photodynamic therapy, imiquimod, chemical exfoliation with trichloroacetic acid and diclofenac gel, for multiple AK and FC. The choice of therapy should be based on multiple factors, such as efficacy, tolerability, patient risk profile, costs and cosmetic results. Management of AK includes not only treatment but also prevention. Medical devices, such as sunscreens containing liposome-encapsulated DNA repair enzymes, can repair DNA damage associated with chronic UV radiation and reduce the number of new AK lesions. Here we provide therapeutic pearls and expert opinions on the treatment of AK and FC (as monotherapy or in combination) with the overall aim to achieve better, faster, and well-tolerated clinical responses.